On the basis of current findings, we suggest that Losartan treatment shifts NFκB signaling to favor the survival route versus inflammation, fibrosis and apoptosis/damage in the dy2J/dy2J mouse model of MDC1A. The gene discussed is NFKB1; the disease is Congenital muscular dystrophy type 1A.